ArticleFrontiers in molecular neuroscience2024
Open access · goldAbstract read
In one paragraph
Article in Frontiers in molecular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Mapping the Cerebral Organoid Landscape: A Systematic Review of Preclinical 3D Models in Neuroscience.Advanced healthcare materials · 2026Pooled it
- Single cell RNA sequencing and emerging transcriptomic technologies in Alzheimer's disease cerebral organoids: a mini review.Molecular brain · 2026Review
- Protective mutations associated with APOE in Alzheimer's disease.Molecular psychiatry · 2026Review
- Advances in hiPSC-Derived Brain Organoids as a Model to Study Neuroinflammation in Alzheimer's Disease.Journal of neurochemistry · 2026Review
- Modeling Alzheimer's disease with brain organoids: mechanisms, applications, and future directions.Frontiers in cell and developmental biology · 2026Review
- Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch.Frontiers in aging neuroscience · 2026Article
- Review
- The Christchurch point mutation in mouse APOE reduces Aβ-induced tau and α-synuclein pathologies.bioRxiv : the preprint server for biology · 2025Article
- Protective mechanisms against Alzheimer's disease in APOE3-Christchurch homozygous astrocytes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Clinical Significance of APOE4 Genotyping: Potential for Personalized Therapy and Early Diagnosis of Alzheimer's Disease.Journal of clinical medicine · 2025Review
- ApoE3 Christchurch and tau interaction as a protective mechanism against Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- CRISPR/Cas9 and iPSC-Based Therapeutic Approaches in Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2025Review
- Protective genetic variants against Alzheimer's disease.The Lancet. Neurology · 2025Review
- Loss of the APP regulator RHBDL4 preserves memory in an Alzheimer's disease mouse model.Cell death & disease · 2025Article
- Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2025Review
- Amyloid-β predominant Alzheimer's disease neuropathologic change.Brain : a journal of neurology · 2025Article
- Molecular Therapeutics in Development to Treat Alzheimer's Disease.Molecular diagnosis & therapy · 2025Review
- Human brain organoids: an innovative model for neurological disorder research and therapy.Frontiers in cellular neuroscience · 2025Review
- Microglial APOE3 Christchurch protects neurons from Tau pathology in a human iPSC-based model of Alzheimer's disease.Cell reports · 2024Article
- Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
- Update of
Authors and funding
16 authors at 5 institutions in 3 countries.
Paula Perez-CorredorSchepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, Boston, MA, United States.
Timothy E VanderleestSchepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, Boston, MA, United States.
Guido N VacanoVacano Informatics LLC, Arvada, CO, United States.
Justin S SanchezMassachusetts General Hospital and Department of Neurology at Harvard Medical School, Boston, MA, United States.
Nelson D Villalba-MorenoMolecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Claudia MarinoSchepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, Boston, MA, United States.
Susanne KrasemannInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Miguel A Mendivil-PerezThe Neuroscience Group of Antioquia, University of Antioquia, Medellín, Colombia.
David AguillónThe Neuroscience Group of Antioquia, University of Antioquia, Medellín, Colombia.
Marlene Jiménez-Del-RíoThe Neuroscience Group of Antioquia, University of Antioquia, Medellín, Colombia.
Ana BaenaThe Neuroscience Group of Antioquia, University of Antioquia, Medellín, Colombia.
Diego Sepulveda-FallaMolecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Francisco LoperaThe Neuroscience Group of Antioquia, University of Antioquia, Medellín, Colombia.
Yakeel T QuirozMassachusetts General Hospital and Department of Neurology at Harvard Medical School, Boston, MA, United States.
Joseph F Arboleda-VelasquezSchepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, Boston, MA, United States.
Randall C MazzarinoSchepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, Boston, MA, United States.
Universidad de Antioquia · COMassachusetts Eye and Ear Infirmary · USUniversität Hamburg · DEMassachusetts General Hospital · USSmith-Kettlewell Eye Research Institute · US
Funding
Resilience to Cognitive Decline and Resistance to Alzheimer's Disease and Related Neurodegenerative Diseases in Individuals from Colombia with Autosomal Dominant DementiasRM1NS132996 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AGUILLON, DAVID FERNANDO, ARBOLEDA-VELASQUEZ, JOSEPH · 2023 to 2023
$3.8MRelationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8MCharting vascular contributions to white matter disease in familial Alzheimer's disease and CADASILRF1NS110048 · NINDS · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH, SEPULVEDA-FALLA, DIEGO · 2018 to 2019
$3.6MMemory network dysfunction as an early marker of preclinical Alzheimer's DiseaseDP5OD019833 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2014 to 2018
$2.3MNerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's diseaseRF1AG077627 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI AGUILLON, DAVID FERNANDO, CUELLO, A CLAUDIO · 2022 to 2022
$2.0MExploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant MiceUH3NS100121 · NINDS · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH · 2018 to 2020
$739kNIA NIH HHS R01 AG054671NIA NIH HHS RF1 AG077627NIH HHS DP5 OD019833NINDS NIH HHS RF1 NS110048NINDS NIH HHS RM1 NS132996NINDS NIH HHS UH3 NS100121
Abstract
A patient with the
Indexed as
Alzheimer’s diseaseApoEApoE ChristchurchCRISPRiPS cellsPresenilinWnt signaling
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.